For Healthcare Professionals

Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection

clipboard-pencil

About the study

Interleukin 29 (IL-29) is a substance that is produced in the body to help fight viral infections. The purpose of this study is to evaluate the safety and antiviral effects of several different doses of PEG-rIL-29 (a man-made form of IL-29) when it is given in combination with daily oral doses of ribavirin (an antiviral drug) to subjects with hepatitis C infection who have received no prior treatment for this disease.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

  1. No prior therapy for chronic HCV, other than up to 2 weeks of single-agent therapy with a direct-acting antiviral agent, including but not limited to, a protease or polymerase inhibitor
  2. HCV genotype 1, 2, 3, or 4
  3. HCV RNA ≥100,000 IU/mL
  4. ALT and AST ≤5.0 × ULN
  5. Documented absence of cirrhosis
  6. Able to comprehend the investigational nature of this study and sign an informed consent form

EXCLUSION CRITERIA

  1. Mixed genotype HCV infection
  2. Current or prior history of decompensated liver disease
  3. Received any investigational drug, including a direct-acting antiviral agent, within 60 days prior to receiving study drug
  4. Positive test for hepatitis B surface antigen, human immunodeficiency virus (HIV)-1, or HIV2 antibody at screening
  5. Active substance abuse, such as alcohol, or inhaled or injected drugs, within 6 months Additional inclusion and exclusion criteria are specified in the protocol.
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.

Study’s details


Contition

Hepatitis C, Chronic

Age

18+

Phase

Phase 2

Participants needed

600

Est. Completion Date

May 2012

Treatment type

Interventional


Sponsor

ZymoGenetics

ClinicalTrials.gov identifier

NCT01001754

Study number

526H04

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.